March 27, 2014 Dr. Manmohan Singh Hon’ble Prime Minister of India, The Prime Minister’s Office, South Block, Raisina Hill, New Delhi 110011. Tel: 011 23018939; Fax: 011 2301 0233. Email: manmohan@sansad.nic.in Resist the US administration Pressure and Reject the Misleading Allegations of US Business Associations  We the undersigned organizations and individuals are writing this letter…

India’s Supreme Court says drug maker Novartis can’t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth of Novartis’s price. Consumer advocates call it a major advance for access to generic drugs….

[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and against Indian Patent law has finally reached a conclusion. On Apr1, Indian Supreme court dismissed…

13 September 2012, New Delhi. Mr Subramaniam, senior counsel appearing for Novartis, continued his arguments today. Placing on record the Doha Declaration on TRIPS Agreement and Public Health, Mr Subramaniam said that it is important to bear in mind the purpose of the TRIPS Agreement. He said that the purpose of the TRIPS Agreement is…

Novartis case: background and update – Supreme Court of India to recommence hearing 5 September 2011, New Delhi. Tomorrow, a Division Bench of the Supreme Court of India, comprising Justice Dalveer Bhandari and Justice Deepak Verma, will re-commence the hearing of Novartis AG’s (Novartis’) challenge to the order of the Intellectual Property Appellate Board (IPAB)…

Novartis AG v. Union of India and Others, SLP (Civil) Nos. 20539–20549 of 2009 In this case, which is presently before the Supreme Court of India, Novartis AG (Novartis) challenges the order of the Intellectual Property Appellate Board (IPAB) rejecting its patent application for Gleevec (beta crystalline form of imatinib mesylate), an anti-cancer drug used…

12 September 2012, New Delhi. Continuing arguments on behalf of Novartis, Mr Gopal Subramaniam, senior counsel, took the Bench through the Complete Specification of Novartis’ patent application for the beta-crystalline form of imatinib mesylate that was filed before the Patent Controller in India. He said that it has to be ascertained whether the application has…

22 August 2012, New Delhi. As directed by the Supreme Court of India on 10 July 2012, the petition filed by Novartis AG, challenging the Intellectual Property Appellate Board’s rejection of its appeal against the Indian Patent Office’s refusal to grant it a patent for the beta-crystalline form of imatinib mesylate, and related matters were…

2014 © Copyright - Lawyers Collective Designed by CGD